Clinical evidence is the body of clinical data and clinical evaluation results that, in sufficient amount and quality, lets a qualified assessor confirm a medical device is safe and delivers its intended clinical benefit when used as intended. Under EU MDR 2017/745, it underpins conformity with the general safety and performance requirements.
What is clinical evidence?
Clinical evidence is a defined regulatory concept, not a loose synonym for “study results.” EU MDR 2017/745 Article 2(51) frames it as the combination of clinical data and the clinical evaluation that interprets that data. Clinical data on its own (Article 2(48)) is the raw input: information about safety or performance generated from use of the device. Clinical evidence is the qualified conclusion you reach after appraising that data against the device’s claimed benefit and risk profile.
It spans the whole device lifecycle. Manufacturers start building it during development, consolidate it for the conformity assessment, and refresh it through post-market surveillance for as long as the device is on the market.
Why clinical evidence matters in medical device development
Clinical evidence is the basis on which a notified body or regulator decides whether a device can be placed on the market and stay there. Article 61(1) of the EU MDR requires that conformity with the general safety and performance requirements be confirmed by clinical data providing sufficient clinical evidence. Without it, the technical documentation fails review and CE marking stalls.
The commercial stakes are large. Clinical evaluation is among the most expensive parts of a conformity assessment, and gaps tend to surface late. Weak evidence triggers deficiency letters, repeated questions, and sometimes a demand for a new clinical investigation that adds quarters to the timeline.
It also drives audit and liability exposure. Post-market data that contradicts pre-market claims must feed back into the evaluation. A benefit-risk shift that is not reflected in the clinical evidence is a finding waiting to happen, and a patient-safety problem before it is a paperwork one.
How clinical evidence is built
Clinical evidence is generated through the clinical evaluation process, a structured appraisal that gathers and weighs every relevant source. The core sources of clinical data recognized under EU MDR Article 2(48) are:
- Clinical investigations of the device itself.
- Clinical investigations or studies in scientific literature for a device shown to be equivalent.
- Peer-reviewed reports of other clinical experience with the device or an equivalent device.
- Clinically relevant information from post-market surveillance, in particular post-market clinical follow-up (PMCF).
The evaluation appraises each source for relevance, methodological quality, and weight, then reaches a documented conclusion about safety and clinical benefit. That conclusion is captured in the Clinical Evaluation Report (CER), the central output that the notified body reviews. MDCG 2020-6 gives guidance on what counts as “sufficient” clinical evidence, since the regulation itself does not put a fixed threshold on it; the required level scales with device risk class, novelty, and the strength of the claims being made.
The amount needed is not uniform. A well-established Class I device may rely largely on literature and equivalence, while a Class III or implantable device generally needs its own clinical investigation, with limited exceptions. For software as a medical device, MDCG 2020-1 applies the same principles to scientific validity, analytical performance, and clinical performance.
Common challenges and best practices
The most frequent failure is treating clinical evidence as a document written at the end rather than a plan set at the start. Teams that draft a Clinical Evaluation Plan (CEP) early, define the intended purpose and clinical benefit precisely, and map each claim to a data source avoid the scramble before submission.
Equivalence is a second trap. Claiming equivalence to a marketed device shifts the burden to proving technical, biological, and clinical similarity in detail, and notified bodies apply that test strictly. Many legacy claims that passed under the older Medical Device Directive no longer hold.
A third issue is letting pre-market and post-market evidence drift apart. PMCF is not optional. It feeds the periodic safety update report (PSUR) and the CER, and the loop has to stay closed. Treat the CER as a living file with an update cadence tied to risk class, not a one-time deliverable.
How SJML helps with clinical evidence
Syrma Johari MedTech (SJML) supports clinical evidence work as part of its Compliance-as-a-Service offering. The QARA team handles clinical evaluation across the document set, including Clinical Evaluation Plans (CEP), Clinical Evaluation Reports (CER), literature review and appraisal, the summary of safety and clinical performance (SSCP), and clinical data management. On the post-market side, SJML plans and runs post-market surveillance and PMCF, prepares PSUR and PMSR documentation, and manages vigilance and EUDAMED activity. This spans EU MDR and IVDR pathways and scales from startups to large OEMs.
Frequently Asked Questions
Clinical data is the raw input: information on safety or performance generated from device use, sourced from investigations, literature, equivalence, or post-market data. Clinical evidence is the qualified conclusion drawn from appraising the data through clinical evaluation. Under EU MDR 2017/745, clinical data is a component of clinical evidence, not the same thing.
Yes. Clinical evidence is required for every device class under the EU MDR, including Class I. The level needed scales with risk, novelty, and the claims made, but no class is exempt from clinical evaluation. Even where generating new clinical data is not required, a Clinical Evaluation Report must still document the justification.
Sufficient clinical evidence means clinical data and evaluation results of sufficient amount and quality to allow a qualified assessment that the device is safe and meets its intended clinical benefit. The EU MDR does not set a fixed threshold; MDCG 2020-6 explains that sufficiency depends on device characteristics, risk class, and the specific claims being supported.
Post-market surveillance and PMCF feed new clinical data back into the clinical evaluation throughout a device’s market life. This data can confirm the original benefit-risk conclusion or flag a shift that requires the Clinical Evaluation Report, PSUR, and risk file to be updated. Clinical evidence is maintained continuously, not fixed at launch.
Related Terms
- Clinical Evaluation Report (CER)
- Post-Market Clinical Follow-Up (PMCF)
- Clinical Investigation (ISO 14155)
- General Safety and Performance Requirements (GSPR)
- Post-Market Surveillance (PMS)
